ClinicalTrials.gg
CompletedNCT02087007STELLAUpdated May 4, 2017

A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina

A Phase 3 interventional study of Cilostazol and placebo in Vasospastic Angina, sponsored by Korea Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-05-04.

Sponsored by Korea Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Angina Pectoris, Variant with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Angina Pectoris, Variant · Korea, Republic of.

Enrollment
6th of 10
100 · median 118
Started
2013
with 2 others
Phase 3
2 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
3 of 11
Korea Otsuka Pharmaceutical Co., Ltd.

Among the 11 studies in Angina Pectoris, Variant with a site in Korea, Republic of, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2013, is one of 2 in phase 3, and was the 5th registered.

Angina Pectoris, Variant

34 studies on the registry are indexed under Angina Pectoris, Variant; 10 are open to participants now.

Browse Angina Pectoris, Variant studies →

Open to participants now

2 of the 11 studies in Angina Pectoris, Variant with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 9 Angina Pectoris, Variant studies recruiting now, 8 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Angina Pectoris, Variant with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of KFDA.

Each subject will participate around 7 weeks, which include the 2 weeks Amlodipine run-in period, 4 weeks double blind period and 1 week safety follow up period

Read the detailed description

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel group, Therapeutic confirmatory Study.

The subject who has at least one episode of chest pain weekly and at least two episodes of chest pain during last week despite Amlodipine 5mg qd taking during 2 weeks will have treatment of Pletaal(Cilostazol) or Placebo for 4 weeks. Pletaal(Cilostazol) is taken 100mg oral tablets bid during 2 weeks after dosing of Pletaal(Cilostazol) 50mg oral tablets bid during 2 weeks. Placebo of Pletaal(Cilostazol) is used as the control medication.

03

Conditions studied

  • Vasospastic Angina

Keywords

  • Treatment for vasospastic angina
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study :

  1. Male or female 20 or over the age of 20 and under the age of 80.
  2. Patients showing angina attack even while resting during the screening, diagnosed with vasospastic angina within the previous 3 months by meeting at least one of the 3 definitions, and accompanying insignificant (stenosis rate \<50%) coronary artery disease documented by coronary angiography within the last 3 months [temporary antispastic agents (monotherapies or a combination of Verapamil and Nitroglycerin, anticoagulants) for coronary angiography are allowed]

    • Chest pain accompanied by at least 2 temporary, closely located ST elevations or depressions of 0.1mV or greater in the absence of ergonovine provoked coronary angiography.
    • Positive Intracoronary (IC) or Intravenous (IV) Ergonovine provocation test; ischemic change accompanied by chest pain and spasm reducing the coronary diameter by 90% or more (at least 2 temporary, closely located ST elevations or depressions of 0.1mV or greater on 12-lead ECG)
  3. Patients who reported at least 1 episode of chest pain in a week during amlodipine run-in period and at least 2 episodes in the final week.
  4. Women who had been menopausal or sterile for at least 1 year, or women of who agree to practice a measure throughout the clinical trial (e.g., hormonal contraceptives, intrauterine devices, condom + spermicidal agents, diaphragm + spermicidal agents, and partner's infertility)
  5. Subjects who signed a written agreement indicating that they were given full explanations of the clinical trial and are willing to participate in the clinical trial.

Subjects presenting with any of the following will not be included in the study:

  1. Subjects who used Cilostazol within 3 months before the screening visit
  2. Subjects who used antiplatelet drugs, including Aspirin, Clopidogrel, Ticlopidine and Sarpogrelate, or PDE3 inhibitors of the same class as Cilostazol, such as Amrinone, Milrinone and Enoximone, after the initiation of the amlodipine run-in period
  3. Subjects who used oral anticoagulants, such as warfarin, within 1 months prior to the screening visit
  4. Subjects who used any of the following drugs within 1 week prior to the screening visit

    • CCBs apart from amlodipine
    • Beta-blockers or alpha-blockers
    • Oral nitrate, excluding nitroglycerin sublingual tablet, Nicorandil
    • Vitamin E preparations
    • Estrogens
  5. History of myocardial infarction or with myocardial infarction mediated by vasospastic angina at the time of screening
  6. History of a life-threatening vasospastic event (e.g., ventricular tachycardia, atrial fibrillation or syncope)
  7. History of stroke, intracranial hemorrhage or (TIA)
  8. Hemorrhage (hemophilia, capillary fragility, upper gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.) or such predisposition (active peptic ulcer, hemorrhage suspected at Cilostazol administration for surgical wound within the last 3 months, proliferative diabetic retinopathy)
  9. History of to the ingredients of Cilostazol, amlodipine, dihydropyridines such as nitroglycerine, and nitrates
  10. Severe aortic stenosis
  11. History of shock
  12. Hypotension with systolic pressure of below 90mmHg at screening
  13. Severe anemia with 6.5g/dl or below at screening
  14. History of glaucoma
  15. ST change abnormality not interpretable on ECG at screening
  16. Congestive heart failure with \<40% on echocardiography at screening or within the last 3 months
  17. Atrial fibrillation or beyond moderate valvular heart disease
  18. Left main coronary spasm suspected or confirmed by coronary angiography or ergonovine provoked coronary angiography
  19. History of coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)
  20. Heart rate >100 bpm at screening via vital sign: tachycardia
  21. Uncontrolled hypertension with systolic pressure ≥ 160 mmHg or diastolic pressure ≥ 100 mmHg at screening
  22. Creatinine level ≥ 1.5 mg/dL at screening
  23. or ALT > x3 (Upper Limit of Normal) at screening
  24. count \< 100,000mm3 at screening
  25. of QTcB > 450 msec in male and QTcB>470 msec in female subjects at screening
  26. Women of childbearing potential with positive pregnancy test at screening
  27. Women who did not agree to practice a contraceptive measure, pregnant or lactating women
  28. Drug compliance of less than 80% during 2-week amlodipine run-in period
  29. Subjects otherwise judged by the investigator to be inappropriate for inclusion in the trial
  30. Subjects who used another products within 2 months prior to the randomization
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    group 1

    Cilostazol 50mg, Cilostzaol 100mg

    Drug: Cilostazol

  • Placebo comparator
    group 2

    placebo

    Drug: placebo

Interventions

  • 100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks

  • Drugplacebo

    100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks

06

What researchers measure

Primary outcomes

  1. Chest Pain Frequency

    Change of the chest pain frequency on the final a week after IP dosing from a week before IP dosing

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Percent change of the chest pain frequency

    Percent change of the chest pain frequency on the final a week after IP dosing from a week before IP dosing

    Time frame: Baseline and Week 4

  2. Proportion of subjects without chest pain

    Proportion of subjects without chest pain on the final a week after IP dosing

    Time frame: 4 weeks

  3. total chest pain intensity

    Change of the total pain intensity on the final a week after IP dosing from a week before IP dosing

    Time frame: Baseline and Week 4

  4. average pain intensity(the total pain intensity/the number of pain)

    Change of the average pain intensity(the total pain intensity/the number of pain) on the final a week after IP dosing from a week before IP dosing

    Time frame: Baseline and Week 4

  5. total nitroglycerin sublingual consumption

    Change of the total nitroglycerin sublingual consumption of the final a week after IP dosing from a week before IP dosing

    Time frame: Baseline and Week 4

07

Study locations

1 site
  • Yangsan Busan University Hospital
    Busan, 626-770, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2014
First posted
Mar 14, 2014
Start
Nov 2013
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
May 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02087007
Responsible party
Sponsor
First posted
Mar 14, 2014
Start date
Nov 2013
Primary completion
Jul 2015
Completion
Jul 2015
Last update
May 4, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion